SB3000 the life science technology company establishes its HQ in Copenhagen

Swedish Biomimetics 3000 Ltd, a life science technology company which has developed a world leading green technology platform used in the continuous manufacturing of pharmaceuticals, has established a new head office and scientific research facilities in Copenhagen. The company, which is called Swedish Biomimetics 3000 ApS, believes that it will benefit from the sector specific expertise in Denmark in expanding its capabilities. Going forward, the company will have key operations in both the UK and Denmark.

SB3000 ApS is initially focused on replacing traditional batch manufacturing in the production of peptide medicines, which are particularly expensive and environmentally damaging to produce and are holding back research into the development of new medicines. The company, has recently signed a research agreement with a top-ten global pharma company and obtained a letter of intent from a top EU based specialty pharma company which has initiated negotiations on a commercial agreement.

There is huge pressure by both regulatory authorities such as the FDA and international agreements to move to continuous manufacturing and reduce the amount of toxic chemicals used in the production of medicines. Denmark’s internationally acknowledged leadership in peptide processing and its expertise in green chemistry provides the company with an environment that will help it to further develop its groundbreaking µLOT® Technology. It will continue to work in close collaboration with both Copenhagen University and leading industry life science companies in both Denmark and Sweden.

Swedish Biomimetics 3000® ApS
Amaliegade 3 1256
Copenhagen
Denmark
Email: info@SB3000.tech
www.SB3000.tech

Press Enquiries: Leonie Onslow or Simon Vane Percy, Vane Percy & Roberts, 00 44 1737 821890/00 44 7710 005910

SB3000 ApS is dedicated to developing green manufacturing technology solutions for continuous manufacturing in the pharmaceutical industry. Over the last few years the company has been developing its μLOT® solid phase, continuous manufacturing technology for the manufacture of peptide medicines with the potential to expand the use of the µLOT® technology into many other manufacturing applications.

This release was published on openPR.